Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopecia

Concert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia areata (AA), a common cause of hair loss, and says it hopes to report results in the second half of 2022.